Save time and get answers to complex questions with AI chat
Brenzavvy discontinuation?How long have hydroxyzine pamoate been on the market?Pramlintide fda approval date?Drugpatentwatch skyrizi biologic patent analysis?Dabrafenib patent expiration?
See the DrugPatentWatch profile for acalabrutinib
The FDA approved acalabrutinib (Calquence) for the first time on February 28, 2017, for adults with mantle cell lymphoma (MCL). If you need the approval dates for other indications (e.g., CLL/SLL or GVHD), I can provide those as well.
Other Questions About Acalabrutinib :